• Sun Pharma’s consolidated revenues for the quarter ended March (Q4FY22) were down 7% quarter-on-quarter (QoQ). On a year-on-year (YoY) basis, it witnessed a growth of 11%.
  • Its expenses for the quarter were down 2% QoQ and up 9% YoY
  • The company reported a net loss of Rs 2,277 crore in Q4FY22 as against a net profit of Rs 894 crore in Q4FY21.

Sun Pharma’s Financial Statements for Q4FY22::

(Rs, crores) Q4FY21 Q3FY22 Q4FY22 QoQ (%) YoY (%)
Total Income 8,634 10,296 9,560 -7% 11%
Total Expenses 7,058 7,829 7,700 -2% 9%
Profit before tax 903 2,466 -2,076 - -
Tax 55 335 147 -56% 167
Profit after tax 894 2,059 -2,277 - -
Earnings per share 3.7 8.6 -    

Data Source: BSE, Company announcements

Want to keep a tab on Indian listed companies? Open an account and get daily stock research updates from Kotak Securities.

The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

浩方电竞 pc蛋蛋28下载手机版 pc28加拿大开奖详情及时 英雄联盟竞猜现场投注网 09电竞下注抽注官网 英雄联盟平台赛程